Dangerous
Medication


 
Medication:

First Name:

Last Name:

Address:

City:

State:

Zip:

Home Phone:

Daytime Phone:

E-Mail:

Case Information:

    

Dangerous Medication
 
THE LAW FIRM OF ALLEN L. ROTHENBERG

FDA ALERT
Raptiva
We can help. If you have suffered from any of the deadly side effects while taking Raptiva® (efalizumab) or if a loved one died from progressive multifocal leukoencephalopathy (PML) while on Raptiva please fill out the form on this page or call 1-800-624-8888.

Food and Drug Administration Issues Safety Alert on Raptiva

The psoriasis drug Raptiva, manufactured by Genentech, Inc. and approved by the Food and Drug Administration (FDA) in 2003 has been linked to several deadly side effects. On February 19, 2009, the FDA announced three cases and a possible fourth of PML, a serious brain infection, were likely caused by Raptiva. Three of the four patients have died as a result of their illness. The FDA asked Genetech in October, 2008, to add a black box warning to Raptiva listing PML as a possible side effect, as well as other dangerous conditions. PML causes serious neurological problems for those who survive the disease. Around 80 percent of those who develop PML die within six months.
Raptiva
Dangerous side effects of Raptiva may include:
  • Progressive multifocal leukoencephalopathy (PML)
  • Bacterial sepsis
  • Invasive fungal disease
  • Viral meningitis
  • On April 8, 2009, Genentech WITHDREW RAPTIVA FROM THE U.S. MARKET.

    If you or a loved one has taken Raptiva® and developed any of the dangerous side effects listed above, please contact an expert Raptiva injury attorney at
    The Law Firm of Allen L. Rothenberg

    1-800-624-8888 or 1-800-ROTHENBERG
    for a free consultation or submit a free online case evaluation.
    The case evaluation is free, and remember, we charge no fee unless we get you money.
    ©2009 The Law Firm of Allen L. Rothenberg. The Injury Lawyer. DangerousMedication.com All rights reserved.
    While this firm maintains joint responsibility, cases of this type may be referred to co-counsel for principal responsibility